Literature DB >> 22359344

Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis.

Susanna A McColley1, Clement L Ren, Michael S Schechter, Warren E Regelmann, David J Pasta, Michael W Konstan.   

Abstract

OBJECTIVES: To characterize the onset of persistent signs and symptoms of cystic fibrosis (CF) lung disease and identify characteristics that predict onset. STUDY
DESIGN: Patients in the Epidemiologic Study of CF who were <4 years of age at enrollment and had ≥2 years of follow-up were included. We defined persistence as a sign or symptom that was present during two consecutive encounters separated by 60-365 days, and persistent clubbing as ≥50% of encounters with clubbing within 365 days. Predictors were assessed in a Cox proportional hazards model for age at first occurrence of each symptom.
RESULTS: Each sign or symptom met the criterion of persistence in a substantial proportion of patients during a follow-up period of 7 ± 3 years (mean ± SD; range 2-12). Risk factors that predicted earlier onset of signs and symptoms included pancreatic enzyme use, Pseudomonas aeruginosa infection, and prior diagnosis of asthma. Other risk factors had variable effects on signs and symptoms.
CONCLUSIONS: Signs and symptoms of lung disease begin early in CF. Risk factors previously reported for lower forced expiratory volume in 1 sec are also associated with earlier onset of persistent signs and symptoms of CF lung disease, but their impact varies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22359344      PMCID: PMC4182956          DOI: 10.1002/ppul.22519

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  19 in total

1.  Is there still a gender gap in cystic fibrosis?

Authors:  Nisha Verma; Andrew Bush; Roger Buchdahl
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

2.  Case-mix adjustment for evaluation of mortality in cystic fibrosis.

Authors:  Gerald T O'Connor; Hebe B Quinton; Richard Kahn; Priscilla Robichaud; Joanne Maddock; Thomas Lever; Mark Detzer; John G Brooks
Journal:  Pediatr Pulmonol       Date:  2002-02

3.  Lung function decline from adolescence to young adulthood in cystic fibrosis.

Authors:  Stacy L Vandenbranden; Ann McMullen; Michael S Schechter; David J Pasta; Rory L Michaelis; Michael W Konstan; Jeffrey S Wagener; Wayne J Morgan; Susanna A McColley
Journal:  Pediatr Pulmonol       Date:  2011-08-24

4.  Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; F Accurso; D Armstrong; R Castile; K Grimwood; P Hiatt; K McCoy; S McNamara; B Ramsey; J Wagener
Journal:  Pediatr Pulmonol       Date:  1999-11

5.  Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada.

Authors:  W J Morgan; S M Butler; C A Johnson; A A Colin; S C FitzSimmons; D E Geller; M W Konstan; M J Light; H R Rabin; W E Regelmann; D V Schidlow; D C Stokes; M E Wohl; H Kaplowitz; M M Wyatt; S Stryker
Journal:  Pediatr Pulmonol       Date:  1999-10

6.  Improved survival among young patients with cystic fibrosis.

Authors:  Michal Kulich; Margaret Rosenfeld; Christopher H Goss; Robert Wilmott
Journal:  J Pediatr       Date:  2003-06       Impact factor: 4.406

7.  Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis.

Authors:  Michael W Konstan; Steven M Butler; Mary Ellen B Wohl; Marcia Stoddard; Robert Matousek; Jeffrey S Wagener; Charles A Johnson; Wayne J Morgan
Journal:  J Pediatr       Date:  2003-06       Impact factor: 4.406

8.  Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis.

Authors:  Philip M Farrell; Zhanhai Li; Michael R Kosorok; Anita Laxova; Christopher G Green; Jannette Collins; Hui-Chuan Lai; Linda M Makholm; Michael J Rock; Mark L Splaingard
Journal:  Pediatr Pulmonol       Date:  2003-09

9.  Structural airway abnormalities in infants and young children with cystic fibrosis.

Authors:  Frederick R Long; Roger S Williams; Robert G Castile
Journal:  J Pediatr       Date:  2004-02       Impact factor: 4.406

10.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08
View more
  6 in total

1.  Early childhood wheezing is associated with lower lung function in cystic fibrosis.

Authors:  Clement L Ren; Michael W Konstan; Margaret Rosenfeld; David J Pasta; Stefanie J Millar; Wayne J Morgan
Journal:  Pediatr Pulmonol       Date:  2013-10-01

2.  Prevalence and Determinants of Wheezing and Bronchodilatation in Children With Cystic Fibrosis: A Retrospective Cohort Study.

Authors:  Francois Galodé; O Ladipo; A Andrieux; H Feghali; S Bui; Michael Fayon
Journal:  Front Pediatr       Date:  2022-05-12       Impact factor: 3.569

3.  Translocon-independent intracellular replication by Pseudomonas aeruginosa requires the ADP-ribosylation domain of ExoS.

Authors:  Victoria Hritonenko; David J Evans; Suzanne M J Fleiszig
Journal:  Microbes Infect       Date:  2012-08-30       Impact factor: 2.700

Review 4.  Epidemiologic Study of Cystic Fibrosis: 25 years of observational research.

Authors:  Michael W Konstan; David J Pasta; Donald R VanDevanter; Jeffrey S Wagener; Wayne J Morgan
Journal:  Pediatr Pulmonol       Date:  2021-01-12

5.  Pseudomonas aeruginosa utilizes the type III secreted toxin ExoS to avoid acidified compartments within epithelial cells.

Authors:  Susan R Heimer; David J Evans; Michael E Stern; Joseph T Barbieri; Timothy Yahr; Suzanne M J Fleiszig
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

6.  Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.

Authors:  Annie Dupuis; Katherine Keenan; Chee Y Ooi; Ruslan Dorfman; Marci K Sontag; Lutz Naehrlich; Carlo Castellani; Lisa J Strug; Johanna M Rommens; Tanja Gonska
Journal:  Genet Med       Date:  2015-06-18       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.